Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Semaglutide Formulations (DV3396 vs PDS290) in Overweight or Obesity
NCT04012255Phase 1Terminated
- Sponsor
- Novo Nordisk
- Start
- Jul 2019
- Primary completion
- Aug 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the semaglutide concentration-time curve (0-168h) at steady state (2.4 mg) and Maximum observed semaglutide concentration at steady state (2.4 mg). Started Jul 2019; status: terminated.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04012255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04012255.